Mar 27, 2025
CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress
Mar 25, 2025
CStone to Showcase Five Latest Research Achievements at AACR 2025
Mar 23, 2025
CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer
Mar 05, 2025
CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL
Mar 03, 2025
CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody
Feb 09, 2025
CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline
Jan 26, 2025
CStone Partners with SteinCares to Market Sugemalimab in Latin America
Dec 22, 2024
CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody
Dec 08, 2024
Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting
Oct 28, 2020
CStone and LegoChem Biosciences Enter Global Licensing Agreement for New Antibody Drug Conjugate
Oct 26, 2020
CStone and EQRx Enter Global Strategic Partnership for Two Immune Checkpoint Inhibitors: sugemalimab (anti-PD-L1) and CS1003 (anti-PD-1)
Oct 11, 2020
CStone Announces Completion of $200 million Share Sale to Pfizer
Aug 30, 2020
CStone Receives US FDA IND Clearance for CS1001-201 Study to Evaluate Anti-PD-L1 Monoclonal Antibody Sugemalimab Monotherapy in R/R ENKTL
Apr 22, 2020
CStone announces acceptance of its first New Drug Application in mainland China by the National Medical Products Administration, for the first-in-class precision therapy avapritinib in two gastrointestinal stromal tumor indications
Jan 24, 2020
CStone announces first patient dosed in the global proof-of-concept study of CS1001 in combination with Bayer's regorafenib
Jan 23, 2020
CStone successfully hosted the first U.S. R&D Day in New York
Jan 08, 2020
CStone announces first patient dosed in the Phase III trial of CS1001 in combination with chemotherapy in first-line esophageal squamous cell carcinoma
Jan 06, 2020
CStone Pharmaceuticals and Blueprint Medicines Initiate Phase 1b/2 Clinical Trial of Fisogatinib in Combination with CS1001 for Patients with Hepatocellular Carcinoma
Dec 12, 2019
CStone completes registration filing for the Phase I trial of its tumor immune microenvironment modulator CS3005 to enable study initiation in Australia
Dec 10, 2019
CStone announces enrollment target reached in the global Phase III VOYAGER trial of avapritinib in Chinese patients with third-line GIST